Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: The Observational Study of Severe Osteoporosis (OSSO)

Osteoporosis International

Volumn 19, Issue 4, 2008, Pages 493-501

  Cooper, C ^a   Jakob, F ^b   Chinn, C ^c   Martin Mola, E ^d   Fardellone, P ^e   Adami, S ^f   Thalassinos, N C ^g   Melo Gomes, J ^h   Torgerson, D ⁱ   Gibson, A ^c   Marin, F ^c  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c ELI LILLY AND COMPANY   (United States)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f Ospedale di Valeggio sul Mincio   (Italy)

^g EVANGELISMOS HOSPITAL   (Greece)

^h INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

ⁱ UNIVERSITY OF YORK   (United Kingdom)

Author keywords

EQ 5D; Fracture; Menopause; Osteoporosis; QUALEFFO; Quality of life

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM; FLUORIDE; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; THYROID HORMONE; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; COMORBIDITY; FEMALE; FRACTURE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; BONE DENSITY; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; STATISTICS; TREATMENT FAILURE; WOMEN'S HEALTH;

ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT FAILURE; WOMEN'S HEALTH;

EID: 47249142880     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0488-8     Document Type: Article

References (49)

1. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010-2018
2. Cumming SR, Melton LJ III (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767
3. Marcus R, Wong M, Heath H et al (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:1535-1541
4. Black DM, Thompson DE, Bauer DC et al, for the Fit Research Group (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118-4124
5. Maricic M, Adachi JD, Sarkar S et al (2002) Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162:1140-1143 (Pubitemid 34522401)
6. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised control trial. JAMA 282:1344-1352
7. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of the effect of alendronate on risk fracture in women existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
8. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. JAMA 282:637-645 (Pubitemid 29384151)
9. Chesnut CH, Silverman S, Andriano K et al (2000) A randomised trial of nasal spray calcitonin in postmenopusal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109:267-276
10. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
11. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468 (Pubitemid 38133766)
12. Ettinger B, Pressman A, Schein J et al (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J Manag Care Pharm 4:488-492
13. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259-262 (Pubitemid 40826240)
14. Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medications. Arch Inter Med 165:2414-2419
15. Turbi C, Herrero-Beaumont G, Acebes JC et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, non-randomized, observational study. Clin Ther 26:245-256 (Pubitemid 38339016)
16. Tosteson AN, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216
17. Badamgarav E, Fitzpatrick LA (2006) A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc 81:1009-1012 (Pubitemid 44175010)
18. NICE Guideline TA087. The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women. [http://www.nice.org.uk/page.aspx?o=115560]. Accessed: 08 March 2007
19. Läkemedelsförmånsnämnden. Forsteo får fortsatt subvention med ny begränsning. [http://www.lfn.se/LFNTemplates/Ptjanst- 1146.aspx]. Accessed: 08 March 2007
20. Lems WF, Hamdy NAT, Netelenbos JC (2006) Teriparatide: an anabolic drug for the treatment of patients with osteoporosis. Ned Tijdschr Geneeskd 150:132-137 (Pubitemid 43143478)
21. Jakob F, Marin F, Martin-Mola E et al (2006) Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Q J Med 99:531-543 (Pubitemid 44304838)
22. Oleksik A, Lips P, Dawson A et al (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent fractures. J Bone Miner Res 15:1384-1392 (Pubitemid 30413872)
23. Lips P, Cooper C, Agnusdei D et al (1999) Quality of life in patients with vertebral fractures: validation of the quality of life questionnaire of the European Foundation for Osteoporosis (Qualeffo). Osteoporos Int 10:150-160 (Pubitemid 29462204)
24. Oleksik AM, Ewing S, Shen W et al (2004) Impact of incident vertebral fractures on health-related quality of life (HRQoL) in post-menopausal women with prevalent vertebral fractures. Osteoporos Int 16:861-870
25. The EuroQol Group (1990) EuroQoL-a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
26. Marra CA, Woolcott JC, Kopec JA et al (2005) A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Social Sci Med 60:1571-1582
27. de Vries M, Ouwendijk R, Kessels AG et al (2005) Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease. J Vasc Surg 41:261-268 (Pubitemid 40342477)
28. Wasserfallen J-B, Halabi G, Saudan P et al (2004) Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 19:1594-1599 (Pubitemid 38786756)
29. Hall SE, Criddle RA, Comito TL, Prince RL (1999) A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508-515
30. Fletcher A, Gore S, Jones D et al (1992) Quality of life measures in health care. II. Design, analysis and interpretation. BMJ 305:1145-1148
31. Lips P, Cooper C, Agnusdei D et al (1997) Quality of life as outcome in the treatment of osteoporosis; the development of a questionnaire for quality of life by the European Foundation for osteoporosis. Osteoporos Int 7:36-38 (Pubitemid 27077784)
32. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095-1108
33. Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604 (Pubitemid 38393794)
34. van Schoor NM, Smit JH, Twisk JWR, Lips P (2005) Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study. Osteoporos Int 16:749-756
35. Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375-382 (Pubitemid 38953182)
36. Lindsay R, Silverman SL, Cooper C et al (2001) Risk of a new vertebral fracture in the year following a fracture. JAMA 285:320-323 (Pubitemid 32095035)
37. Marin F, Tynan AJ, Mullarney T (2006) Study description and baseline characteristics of the population in the European Forsteo Observational Study (EFOS). Ann Rheum Dis 65(Suppl II):429
38. Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447-455
39. Borgström F, Zethraeus N, Johnell O et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637-650 (Pubitemid 351878360)
40. Adachi JD, Ioannidis G, Olszynski WP et al (2002) The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskeletal disorders 3:11 (Pubitemid 38994415)
41. Martin AR, Sornay-Rendu E, Chandler JM et al (2002) The impact of osteoporosis on quality-of-life: the OFELY Cohort. Bone 31:2002-2032 (Pubitemid 34754422)
42. O'Neill TW, Cockerill W, Matthis C et al (2004) Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. Osteoporos Int 15:760-765 (Pubitemid 39222660)
43. Brooks R, Rabin R, de Charro F (2003) The measurement and valuation of health status using EQ-5D: a European perspective. Kluwer Academic Publishers, Dordrecht
44. Cockerill W, Lunt M, Siloman AJ et al (2004) Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 15:113-119 (Pubitemid 38252424)
45. Silverman SL, Minshall ME, Shen W et al, on behalf of the Health-Related Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study (2001) The relationship of health related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis. Arthritis Rheum 44:2611-2619
46. Brazier JE, Green C, Kanis JA; Committee of Scientific Advisors International Osteoporosis Foundation (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13:768-776 (Pubitemid 36336721)
47. Honkanen K, Honkanen R, Heikkinen L, Kroger H, Saarikoski S (1999) Validity of self-reports of fractures in perimenopausal women. Am J Epidemiol 150:511-516 (Pubitemid 29407235)
48. Nevitt MC, Cummings SR, Browner WS et al (1992) The accuracy of self-report of fractures in elderly women: evidence from a prospective study. Am J Epidemiol 135:490-499
49. Ismail AA, O'Neill TW, Cockerill W et al (2000) Validity of self-report of fractures: results from a prospective study in men and women across Europe. Osteoporos Int 11:248-254 (Pubitemid 30216177)